Grace Therapeutics, Inc. (GRCE) stock
GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
$1.72−0.03 (-1.71%)
Close on Nov 17, 2026Market cap $36.18MP/E –Yield –
Grace Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Grace Therapeutics's revenue for the twelve months ending Mar 31, 2022 was $100.00M, up 50920.4% year over year. For fiscal 2022 it was $100.00M, up 50920.4% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Mar 31, 2022 | $100.00M | +50920.4% |
| FY2021 | Mar 31, 2021 | $196.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $100.00M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $0 | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $115.00K | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $81.00K | – |
See a number that looks wrong?